척수 자극 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of spinal cord stimulation (SCS) Market

The global spinal cord stimulation (SCS) market represents a rapidly advancing segment within the neuromodulation and chronic pain management landscape. In 2025, the global spinal cord stimulation market size was valued at USD 3.52 billion. The market is projected to expand to USD 3.81 billion in 2026 and further reach USD 7.92 billion by 2034, registering a CAGR of 9.60% during the 2026-2034 forecast period. This growth is primarily supported by rising chronic pain prevalence, increasing adoption of minimally invasive therapies, and continuous technological innovation in neuromodulation devices.

Neuromodulation therapies involve the targeted delivery of electrical or chemical stimuli to specific neural structures. Spinal cord stimulation, one of the most established neuromodulation techniques, works by delivering controlled electrical impulses to the spinal cord, effectively masking pain signals before they reach the brain. The therapy is gaining strong clinical acceptance due to its ability to reduce dependency on opioid medications and improve long-term quality of life for chronic pain patients.

Impact of COVID-19 on the Spinal Cord Stimulation Market

The global COVID-19 pandemic had a significant short-term impact on the spinal cord stimulation market. In 2020, the market experienced a sharp decline of -16.3%, largely due to postponement of elective and non-urgent surgical procedures. According to COVIDSurg, nearly 28.4 million surgeries were canceled or deferred worldwide during the peak 12-week disruption period. Since spinal cord stimulation implantations are categorized as elective (level 5) procedures, demand dropped sharply across all regions.

This impact was reflected in company performance, with Abbott reporting a 30.1% decline in neuromodulation revenues in early 2020, while Boston Scientific recorded a 24.6% sales decline in the same segment. However, post-pandemic recovery led to a rebound in procedural volumes, accelerating market growth beyond pre-pandemic levels.

Market Trends: Shift Toward Non-Opioid Pain Management

A key trend shaping the spinal cord stimulation market is the global shift toward non-opioid alternatives for chronic pain treatment. According to the Centers for Disease Control and Prevention, over 168 million opioid prescriptions were dispensed in the U.S. in 2018, contributing to more than 67,000 overdose-related deaths. These alarming statistics have prompted governments and healthcare systems to actively promote non-opioid therapies, significantly boosting demand for spinal cord stimulation devices.

Regulatory agencies such as the Food and Drug Administration have also accelerated approvals for neuromodulation devices, further strengthening market adoption.

Market Drivers Supporting Market Value Growth

Technological advancements are a major driver of spinal cord stimulation market growth. Manufacturers are focusing on miniaturization, battery longevity, and advanced stimulation waveforms. For instance, Stimwave's ultra-miniaturized SCS systems and novel waveforms such as Differential Target Multiplexed (DTM) SCS have demonstrated superior pain relief outcomes. High-frequency therapies like HF10 are also gaining traction due to improved efficacy compared to conventional stimulation.

Emerging government guidelines are another growth catalyst. In 2019, the National Institute for Health and Care Excellence issued favorable recommendations for HF10-based SCS systems, strengthening physician confidence and accelerating adoption across Europe.

Market Restraints Limiting Adoption

Despite strong growth prospects, the high cost of spinal cord stimulation procedures remains a key restraint. In the U.S., implantation costs range from USD 21,000 to USD 58,000, with annual maintenance costs between USD 5,000 and USD 21,000. Trial procedures alone can cost approximately USD 8,000, creating financial barriers for uninsured or underinsured patients.

Segmentation Insights

By disease indication, failed back surgery syndrome (FBSS) dominated the market with a 47.22% share in 2026, driven by rising spinal surgery volumes. By product, rechargeable spinal cord stimulators led the market with a 64.27% share in 2026, owing to long battery life and lifetime cost savings of up to USD 100,000 per patient. Hospitals remained the leading end-user segment, accounting for 52.73% of the market in 2026, supported by favorable reimbursement and higher surgical volumes.

Regional Outlook (2025-2026 Focus)

North America dominated the global spinal cord stimulation market with a 74.44% share in 2025, generating USD 2.62 billion in market value. The U.S. alone is projected to reach USD 2.59 billion by 2026, supported by strong reimbursement frameworks and early technology adoption. Europe followed, with Germany (USD 0.12 billion) and the UK (USD 0.07 billion) showing steady growth by 2026. Asia Pacific is expected to register the fastest expansion, with China (USD 0.10 billion), Japan (USD 0.09 billion), and India (USD 0.05 billion) benefiting from rising geriatric populations and improving healthcare infrastructure.

Competitive Landscape and Report Scope

The spinal cord stimulation market is moderately consolidated, led by Medtronic, followed by Boston Scientific, Abbott, and Nevro Corp. Strategic acquisitions, continuous R&D investment, and new product launches remain central to competitive positioning. The report comprehensively analyzes market size, market value trends, segmentation, regional performance, drivers, restraints, and competitive dynamics, strictly aligned with 2025, 2026, and 2034 data points.

Conclusion

The spinal cord stimulation market is positioned for robust long-term expansion, supported by a strong recovery from the pandemic-driven slowdown and sustained clinical demand for advanced pain management solutions. With the market valued at USD 3.52 billion in 2025, expected to reach USD 3.81 billion in 2026, and projected to expand to USD 7.92 billion by 2034, spinal cord stimulation has established itself as a core therapy within the neuromodulation landscape. Dominance of North America, rapid uptake of rechargeable devices, rising prevalence of chronic pain conditions such as failed back surgery syndrome, and the global shift toward non-opioid therapies continue to strengthen market value. Although high procedural and maintenance costs remain a limiting factor, ongoing technological innovation, supportive government guidelines, and expanding healthcare infrastructure in emerging regions are expected to sustain market growth throughout the forecast period.

ATTRIBUTES DETAILS

Segmentation

By Product

• Rechargeable
• Non-rechargeable

By Disease Indication

• Failed Back Surgery Syndrome (FBSS)
• Degenerative Disc Disease (DDD)
• Complex Regional Pain Syndrome (CRPS)
• Arachnoiditis
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Geography

• North America
  • By Product
  • By Disease Indication
  • By End User
  • By Country
• Europe
  • By Product
  • By Disease Indication
  • By End User
  • By Country/Sub-region
• Asia Pacific
  • By Product
  • By Disease Indication
  • By End User
  • By Country/Sub-region
• Rest of World
  • By Product
  • By Disease Indication
  • By End User

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Key Indications - For Key Countries/ Regions
• 4.2. Regulatory Scenario - For Key Countries/ Regions
• 4.3. Impact of COVID-19 on Global Spinal Cord Stimulation Market
• 4.4. New Product Launches
• 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships

5. Global Spinal Cord Stimulation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Rechargeable
  • 5.2.2. Non-rechargeable
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Failed Back Surgery Syndrome (FBSS)
  • 5.3.2. Degenerative Disc Disease (DDD)
  • 5.3.3. Complex Regional Pain Syndrome (CRPS)
  • 5.3.4. Arachnoiditis
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Ambulatory Surgery Centers
  • 5.4.3. Specialty Clinics
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of World

6. North America Spinal Cord Stimulation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Rechargeable
  • 6.2.2. Non-rechargeable
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Failed Back Surgery Syndrome (FBSS)
  • 6.3.2. Degenerative Disc Disease (DDD)
  • 6.3.3. Complex Regional Pain Syndrome (CRPS)
  • 6.3.4. Arachnoiditis
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Ambulatory Surgery Centers
  • 6.4.3. Specialty Clinics
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Spinal Cord Stimulation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Rechargeable
  • 7.2.2. Non-rechargeable
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Failed Back Surgery Syndrome (FBSS)
  • 7.3.2. Degenerative Disc Disease (DDD)
  • 7.3.3. Complex Regional Pain Syndrome (CRPS)
  • 7.3.4. Arachnoiditis
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Ambulatory Surgery Centers
  • 7.4.3. Specialty Clinics
• 7.5. Market Analysis, Insights and Forecast - By Countries/ Sub-regions
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Spinal Cord Stimulation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Rechargeable
  • 8.2.2. Non-rechargeable
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Failed Back Surgery Syndrome (FBSS)
  • 8.3.2. Degenerative Disc Disease (DDD)
  • 8.3.3. Complex Regional Pain Syndrome (CRPS)
  • 8.3.4. Arachnoiditis
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Ambulatory Surgery Centers
  • 8.4.3. Specialty Clinics
• 8.5. Market Analysis, Insights and Forecast - By Countries/ Sub-regions
  • 8.5.1. India
  • 8.5.2. Japan
  • 8.5.3. China
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Rest of World Spinal Cord Stimulation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Rechargeable
  • 9.2.2. Non-rechargeable
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Failed Back Surgery Syndrome (FBSS)
  • 9.3.2. Degenerative Disc Disease (DDD)
  • 9.3.3. Complex Regional Pain Syndrome (CRPS)
  • 9.3.4. Arachnoiditis
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Ambulatory Surgery Centers
  • 9.4.3. Specialty Clinics

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2021)
• 10.3. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 10.3.1. Abbott
    • 10.3.1.1. Overview
    • 10.3.1.2. Product
    • 10.3.1.3. SWOT analysis
    • 10.3.1.4. Recent developments
    • 10.3.1.5. strategies
    • 10.3.1.6. financials (based on availability)
  • 10.3.2. Boston Scientific Corporation
    • 10.3.2.1. Overview
    • 10.3.2.2. Product
    • 10.3.2.3. SWOT analysis
    • 10.3.2.4. Recent developments
    • 10.3.2.5. strategies
    • 10.3.2.6. financials (based on availability)
  • 10.3.3. Stimwave LLC
    • 10.3.3.1. Overview
    • 10.3.3.2. Product
    • 10.3.3.3. SWOT analysis
    • 10.3.3.4. Recent developments
    • 10.3.3.5. strategies
    • 10.3.3.6. financials (based on availability)
  • 10.3.4. Medtronic
    • 10.3.4.1. Overview
    • 10.3.4.2. Product
    • 10.3.4.3. SWOT analysis
    • 10.3.4.4. Recent developments
    • 10.3.4.5. strategies
    • 10.3.4.6. financials (based on availability)
  • 10.3.5. Nevro Corp
    • 10.3.5.1. Overview
    • 10.3.5.2. Product
    • 10.3.5.3. SWOT analysis
    • 10.3.5.4. Recent developments
    • 10.3.5.5. strategies
    • 10.3.5.6. financials (based on availability)
  • 10.3.6. Nuvectra
    • 10.3.6.1. Overview
    • 10.3.6.2. Product
    • 10.3.6.3. SWOT analysis
    • 10.3.6.4. Recent developments
    • 10.3.6.5. strategies
    • 10.3.6.6. financials (based on availability)
  • 10.3.7. Other Prominent Players
    • 10.3.7.1. Overview
    • 10.3.7.2. Product
    • 10.3.7.3. SWOT analysis
    • 10.3.7.4. Recent developments
    • 10.3.7.5. strategies
    • 10.3.7.6. financials (based on availability)

11. Strategic Recommendations